Future pharmacologic targets for acute and preventive treatments of migraine

References

• Ramadan NM. Epidemiology and impact of migraine. Continuum: Headache Update 9(1), 9–24 (2003).
   Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral Triptans (serotonin 5-HT agonists) in acute migraine treatment. Lancet 358(9294), 1668–1675 (2001).
   Google Scholar
• Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral mechanisms in migraine. Neurology61(8 Suppl. 4), S9-S20 (2003).
   Google Scholar
• •Outstanding and comprehensive review of migraine mechanisms.
   Google Scholar
• Hargreaves RJ, Shepheard SL. Pathophysiology of migraine — new insights. Can. j Neural. Sci. 26\(Suppl. 3), S12—S19 (1999).
   Google Scholar
• Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the antimigraine drug, sumatriptan. Eur Neural. 31(5), 282–290 (1991).
   Google Scholar
• Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Tends Pharmacol Sci. 14(4) 129–133(1993).
   Google Scholar
• Longmore J, Dowson AJ, Hill RG. Advances in migraine therapy — 5-HT receptor subtype-specific agonist drugs. CUI7: Op. Invest. Drugs1(1), 39–53 (1999).
   Google Scholar
• Moskowitz MA. Trigeminovascular system. Cephalalgia 12(3), 127 (1992).
   PubMed Web of Science ®Google Scholar
• Shepheard S, Edvinsson L, Cumberbatch M et al Possible antimigraine mechanisms of the 5HT1F receptor agonist LY334370. Cephalalgial9(10) 851–858 (1999).
   Google Scholar
• McCall RB, Huff R, Chio CL et al. Preclinical studies characterizing the antimigraine and cardiovascular effects of selective 5-HT(ID) receptor agonist PNU-142633. Cephalalgia 22(10), 799–806 (2002).
   Google Scholar
• Johnson KVV, Schaus JM, Durkin MM et al 5-HTIF receptor agonists inhibit neurogenic dural inflammation in guinea-pigs. Ailitoreport 8(9–10), 2237–2240 (1997).
   Google Scholar
• Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C. Both 5-HTIB and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur j Pharmacol 369(3), 271–277 (1999).
   Google Scholar
• Goldstein DJ, Roon KI, Offen WW et al Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 358(9289), 1230–1234 (2001).
   Google Scholar
• Ramadan, NM, Skljarevski V, Phebus LA, Johnson KW 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 23(8) 776–785 (2003).
   Google Scholar
• ••Reviews the preclinical and clinical datathat assessed the potential link between migraine and serotonin (5-M) iF activation with selective 5-HT1F receptor agonists such as LY334370.
   Google Scholar
• Cutrer FM, Yu XJ, Ayata G, Moskowitz MA, Waeber C. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neurophatmacology 38(7), 1043–1053 (1999).
   Google Scholar
• Gomez-Mancilla B, Cutler NR, Leibowitz MT et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21(7), 727–732 (2001).
   Google Scholar
• Pregenzer JF, Alberts GL, Im WB et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1-selective ligands). BE j Pharmacol 127(2), 468–472 (1999).
   Google Scholar
• Hedqvist P, Fredholm BB. Effects of adenosine on adrenergic neurotransmission; prejunctional inhibition and postjunctional enhancement. Naunyn-Schmiedebergs Airh. Pharmacol 293(3), 217–223 (1976).
   Web of Science ®Google Scholar
• Reeve AJ, Dickenson AH. The roles of spinal adenosine receptors in the control of acute and more persistant nociceptive responses of dorsal horn neurones in the anaesthetized rat. BE j Phatmacol 116(4), 2221–2228 (1995).
   Google Scholar
• Schindler M, Harris CA, Hayes B, Papotti M, Humphrey PPA. Immunohistochemical localization of adenosine Al receptors in human brain regions. Neurosci Lett. 297\(Suppl. 3), 211–215 (2001).
   Google Scholar
• Sollevi A, Belfrage M, Lundeberg T, Segerdahl M, Hansson P Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain61(1), 155–158 (1995).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neural. 55(1), 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine Al receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125 (Pt 6), 1392–1401 (2002).
   PubMedGoogle Scholar
• Bland-Ward PA, Feniuk W, Humphrey PPA. The adenosine Al receptor agonist GR79236 inhibits evoked firing of trigeminal nucleus caudalis (TNC) neurons in the rat. Cephalalgia20(4), 271 (2000).
   Google Scholar
• Honey AC, Bland-Ward PA, Connor HE, Feniuk W, Humphrey PPA. Study of the adenosine Al receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Cephalalgia 22 (4), 260–264 (2002) .
   PubMed Web of Science ®Google Scholar
• Giffin NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H. Effect of the adenosine Al receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 23(4), 287–292 (2003).
   Google Scholar
• Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly cakitonin gene-related peptide. Auton. Nerv. Syst. 70(1–2), 15–22 (1998).
   Google Scholar
• McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: Functional role in cerebro-vascular regulation. Proc. Natl Acad. Sc]. USA. 83(15), 5731–5735 (1986).
   Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22 (1), 54–61 (2002) .
   PubMed Web of Science ®Google Scholar
• Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L In-depth characterization of CGRP receptors in human intracranial arteries. Eur Phannacol 481(2-3), 207–216 (2003).
   PubMed Web of Science ®Google Scholar
• Edvinsson L. New therapeutic target in primary headaches — blocking the CGRP receptor. Expert. Opin. Ther Targets7 (3), 377–383 (2003).
   Google Scholar
• Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 15(4), 277–280 (1995).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neural. 23(2), 193–196 (1988).
   Google Scholar
• Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenyl cyclase. Cephalalgia 16(5), 310–316 (1996).
   PubMed Web of Science ®Google Scholar
• Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of cakitonin gene-related peptide in migraine outside of attacks. Pain 86(1-2), 133–138 (2000).
   PubMed Web of Science ®Google Scholar
• McLatchie LM, Fraser NJ, Main MJ et al RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (6683), 333–339 (1998).
   PubMed Web of Science ®Google Scholar
• Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR. A comparison of the actions of BIBN4096BS and CGRP(8–37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br. Pharmacol 137(1), 80–86 (2002).
   Google Scholar
• Doods H, Hallermayer G, Wu D et al. Pharmacologic profile of BIBN4096BS, the first selective small molecule CGRP antagonist. BE I Pharmacol 129(3), 420–423 (2000).
   Google Scholar
• Oleson J, Diener HC, Husstedt IW et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. Cephalalgia 23(7), 579 (2003).
   Google Scholar
• Watling KJ. Vanilloid receptors. The Sigma- RBI Handbook of Receptor Classification and Signal 7iansduction. Watling KJ (Ed.). Sigma-RBI, Natick, MA, USA, 143–144 (2001).
   Google Scholar
• Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. Pharmacol Exp. Ther. (2004) (In Press).
   Google Scholar
• Diamond S, Freitag F, Phillips S, Bernstein J, Saper J. Intranasal civamide for the acute treatement of migraine headache. Cephalalgia 20 (6), 597–602 (2000) .
   PubMed Web of Science ®Google Scholar
• Saper JR, Klapper J, Ninan MT, Rapoport A, Phillips SB, Bernstein JL. Intranasal civamide for the treatment of episodic cluster headaches. Arch. Neural. 59(6), 990–994 (2002).
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Thompson SW The induction and maintenance of central sensitization is dependent on Nmethyl-D-aspartic acid receptor activation: implications for the treatment of post injury pain hypersensitivity states. Pain 44 (3), 293–299 (1991).
   PubMed Web of Science ®Google Scholar
• Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 15 (1), 29–58 (2001).
   PubMed Web of Science ®Google Scholar
• Nelson IKA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neumlogy 48(5), 1212–1218 (1997).
   PubMed Web of Science ®Google Scholar
• Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesia Scam/. 41(9), 1124–1132 (1997).
   PubMed Web of Science ®Google Scholar
• Simmons RM, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S. Kainate G1uR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neumphalmacology37 (1), 25–36 (1998).
   Google Scholar
• Johnson KW, Dieckman DK, Phebus LA et al G1uR5 antagonists as novel migraine therapies. Cephalalgia 21(4), 268 (2001).
   Google Scholar
• Sang CN, Hostetter MP, Gracely RII et al. AMPA/kainate antagonist LY-293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89(5), 1060–1067 (1998).
   Google Scholar
• Iyengar S, Sang CN, Webster AA, Simmons RMA, Ramadan NM. LY-293558, an ampa/glut5 glutamate receptor antagonist is effective on animal and human models of neuropathic pain. Presented at the 10th World Congness on Pain. San Diego, CA, USA (2002).
   Google Scholar
• Sang CN, Ramadan NM, Wallihan RG et al. LY-293558, a novel AMPA/G1uR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia (2004) (In Press).
   Google Scholar
• Gilron I, Max MB, Lee G et al. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainite antagonist LY-293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol Ther. 68(3), 320–327 (2000).
   Google Scholar
• Ramadan, NM. The link between glutamate and migraine. CNS Spectr 8(6), 446–449 (2003).
   PubMed Web of Science ®Google Scholar
• •Reviews the role of glutamate in migraine pathophysiology as well as the preclinical and clinical data for glutamate receptor subtype antagonists.
   Google Scholar
• Mathew NT, Kailasam J, Meadors L, Chemyschev 0, Gentry P. Intravenous valproate sodium (Depacon) aborts migraine rapidly: a preliminary report. Headache 40 (9), 720–723 (2000) .
   Google Scholar
• Scott V, Belanger J, Krusz JC. Intravenous valproate sodium in the treatment of
   Google Scholar
• Norton J. Use of intravenous valproate sodium in status migraine. Headache 40 (9), 755–757 (2000).
   PubMed Web of Science ®Google Scholar
• Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders 75–79 (2004).
   Google Scholar
• Tanen DA, Miller S, French T, Riffenburgh RII. Intravenous sodium valproate versusprochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann. Emerg: Med. 41(6), 847–853 (2003).
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Olesen J. Nitric oxide theory of migraine. Gun. Neurosci. 5(1), 28–33 (1998).
   Web of Science ®Google Scholar
• Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on central nervous system of nitroglycerin — putative mechanism and mediators. Frog: Neurobial 57(6), 607–624 (1999).
   PubMed Web of Science ®Google Scholar
• Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-B as a molecular target for migraine therapy. Ann. Neural 51(4), 507–516 (2002).
   PubMed Web of Science ®Google Scholar
• Oleson J, Iverson HK, Thomsen LL. Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain. Neural-Tort 4(8), 1027–1030 (1993).
   Google Scholar
• Reuter U, Bolay H, Chiarugi A et al. Nitroglycerin infusion causes a delayed inflammatory response in dura mater. Cephalalgia 21(4), 276 (2001).
   Google Scholar
• Read SJ, Smith MI, Hunter AJ, Parsons AA. Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat. Cephalalgia 17(3), 159–165 (1997).
   PubMed Web of Science ®Google Scholar
• Wei EP, Moskowitz MA, Baccalini P, Kontos HA. Cakitonin gene related peptide mediates nitroglycerin and sodium nitroprusside induced vasodilation in feline cerebral arteries. Om Res. 70(6), 1313–1319 (1992).
   Google Scholar
• Lassen LH, Ashina M, Christiansen I et al Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18(1), 27–32 (1998).
   PubMed Web of Science ®Google Scholar
• Hjorth-Lassen L, Klingenberg Iversen H, Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. Eur j Clin. Pharmacol. 59(7), 499–505 (2003). Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 23(9), 877–86 (2003).
   Google Scholar
• Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 55 (7), 915–920. (2000) .
   PubMed Web of Science ®Google Scholar
• Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289(1), 65–69 (2003).
   PubMed Web of Science ®Google Scholar
• Patema S, Di Pasquale P, D'Angelo A et al. Angiotensin converting enzyme gene deletion polymorphism determines and increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neural 43(3), 133–136 (2000).
   PubMed Web of Science ®Google Scholar
• Bender WI. ACE inhibitors for the prophylaxis of migraine headaches. Headache 35(8), 470–471 (1995).
   PubMed Web of Science ®Google Scholar
• Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BE Med 322(7277), 19–22 (2001).
   PubMedGoogle Scholar
• Watling KJ. Calcium channels. The Sigma-RBI Handbook of Ratptor Classification and Sprat Transduction Watling KJ (Ed.). Sigma-RBI, Natick, MA, USA, 130–131 (2001).
   Google Scholar
• Pietrobon D. Calcium channels and channelopathies of the central nervous system. Mal Neurobial 25 (1), 31–50 (2002).
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson DJ, Goadsby PJ. Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. BE J. Pharmacol. 140 (3), 558–566 (2003).
   Google Scholar
• Wallace MS. Calcium and sodium channel antagonists for the treatment of pain. Can. J. Pain 16(2 Suppl), S80—S85 (2000).
   Google Scholar
• Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci. 22 (5), RC213 (2002).
   Google Scholar
• Ophoff RA, Terwindt GM, Vergouwe MN et al Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4. Cell Tiss. Res. 87(3), 543–552 (1996).
   Google Scholar
• Kors EE, van den Maagdenberg AM, Plomp JJ, Frants RR, Ferrari MD. Calcium channel mutations and migraine. CI.117: Opin. Neural 15(3), 311–316 (2002).
   Google Scholar
• Omote K, Iwasaki H, Kawamata M, Satoh O, Namiki A. Effects of verapamil on spinal anesthesia with local anesthetics. Anesth. Analg: 80(3), 444–448 (1995).
   Google Scholar
• Ramadan, NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 17(2), 73–80 (1997).
   PubMed Web of Science ®Google Scholar
• Ruiz-Nuno A, Villarroya M, Cano-Abad M et al Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility. Eur. j Pharmacol. 411 (3), 289–299 (2001).
   PubMed Web of Science ®Google Scholar
• Galiano L, Matias-Guiu J, Horga JF, Martin R, Falip R, Montiel I. Dotarizine: a double-blind trial in prophylactic treatment of migraine. Cephalalgia 13\(Suppl. 13), 251 (1993).
   Google Scholar
• Horga JF, Matias-Guiu J, Castillo J, Lainez JM, Hernández M, Faura CC. Comparison of dotarizine and pizotifen in prophylactic treatment of migraine: a crossover double-blind multicentre study. 8th World Congress on Pain, Vancouver Canada, 501 (1996).
   Google Scholar
• Diamond S, Ryan RE, Klapper JA et al Dotarizine in the prophylaxis of migraine headache. Headache. 39(5), 350 (1999).
   Google Scholar
• Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. Pharmacol Exp. Ther. 269(3), 1117–1123 (1994).
   Google Scholar
• Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 60(1), 83–90 (1995).
   PubMed Web of Science ®Google Scholar
• Presley R, Charapata S, Staats P et al Intrathecal ziconotide in the treatment of opioid-resistant pain: a controlled clinical trial. American Pain Society Annual Meeting (2000).
   Google Scholar
• Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 85 (1-2), 291–296 (2000).
   PubMed Web of Science ®Google Scholar
• Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl. 4), S2—S8 (2003).
   Google Scholar
• Smith MI, Read SJ, Chan WN et al Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 20 (6), 546–553 (2000).
   Google Scholar
• Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of spreading depression in the anaesthetized cat. Cephalalgla 20(2), 92–99 (2000).
   Google Scholar
• MaassenVanDenBrink A, van den Broek RVVM, de Vries R, Upton N, Parsons AA, Saxena PR The potential antimigraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgla 20(6), 538–546 (2000).
   Google Scholar
• Krymchantowski AV, Bigal ME, Moreira PE New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611–34 (2002).
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgla 17(2), 103–108 (1997).
   PubMed Web of Science ®Google Scholar
• Frietag FG, Collins SD, Carlson HA et al A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology58, 1652–1659 (2002).
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41 (Suppl. 1), S3—S9 (2000).
   Google Scholar
• Brandes JL, Saper JR, Diamond M. Topiramate for migraine prevention: a randomized controlled trial. JA1VI4 291(8), 965–973 (2004).
   Google Scholar
• Fink K, Dooley DJ, Wolfgagn PM et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology42, 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin. Thec 151(3), 145–148 (2000).
   Google Scholar
• Mathew NT Rapoport A, Saper J et al Efficacy of gabapentin in migraine prophylaxis. Headache 41(2), 119–128 (2001) .
   Google Scholar
• Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17(2), 109–112 (1997).
   PubMed Web of Science ®Google Scholar
• Doily 0. Synaptic transmission: inhibition of neurotransmitter release by Botulinum toxins. Headache 43\(Suppl. 1), S16—S24 (2003).
   Google Scholar
• Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43 (Suppl. 1), S9—S15 (2003).
   Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 (6), 445–450 (2000) .
   PubMed Web of Science ®Google Scholar
• Evers S, Rahmann A, Vollmer-Haase J, Husstedt I-W Treatment of headache with botulinum toxin A — a review according to evidence-based medicine criteria. Cephalalgia 22 (9), 699–710 (2002) .
   PubMed Web of Science ®Google Scholar
• Ondo W Vuong K, Derman H. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgla 24(1), 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Welch KMA, Ramadan NM. Mitochondria, magnesium and migraine. Neural Sci. 134,9–14 (1995).
   PubMed Web of Science ®Google Scholar
• Ciancarelli I, Tozzi—Ciancarelli MG, Di Massimo C, Marini C, Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine. Cephalalgia 23(1), 39–42 (2003).
   PubMed Web of Science ®Google Scholar
• Tozzi-Ciancarelli MG, De Matteis G, Di Massimo C, Marini C, Ciancarelli I, Carolei A. Oxidative stress and platelet responsiveness in migraine. Cephalalgia 17(5), 580–584 (1997).
   PubMed Web of Science ®Google Scholar
• Sangiorgi S, Mochi M, Riva R et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgla 14(1), 21–23 (1994).
   PubMed Web of Science ®Google Scholar
• Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM. Low brain magnesium in migraine. Headache 29(9), 590–593 (1989).
   PubMed Web of Science ®Google Scholar
• Boska MD, Welch KM, Barker PB, Nelson JA, Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 58 (8), 1227–1233 (2002) .
   PubMed Web of Science ®Google Scholar
• Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 16(4), 257–263 (1996).
   PubMed Web of Science ®Google Scholar
• Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50 (2), 466–470 (1998).
   Google Scholar
• Rozen TD, Oshinsky ML, Gebeline CA et al Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgla 22(2), 137–141 (2002).
   Google Scholar
• Sandor PS, Clemente LD, Coppola G et al. Coenzyme Q10 for migraine prophylaxis: a randomized controlled trial. Cephalalgia 23(7), 577 (2003).
   Google Scholar
• Pittler M, Ernst E. Cochrane Database Syst Rev 1, CD002286 (2004).
   Google Scholar
• Pfaffenrath V, Diener HC, Fischer M, Friede M, Heneicke-von Zepelin IIf I. Theefficacy and safety of Tanacetumparthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebo-controlled dose response study. Cephalalgia 22 (7), 523–532 (2002) .
   PubMed Web of Science ®Google Scholar
• Eaton J. Butterbur, herbal help for migraine. Natural Pharmacother. 2,23–24 (1998).
   Google Scholar
• Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int. J: Pharmacol Ther. 38(9), 430–435 (2000).
   Google Scholar
• Lipton RB, Gobel H, Winks, K et al. Efficacy of petasites (an extract from petasites rhizome) 50 and 75mg for prophylaxis of migraine: results of a randomized, double-blind, placebo-controlled study. Neurology 58, A472 (2002). Websites
   Google Scholar
• Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine www.aan.com/professionals/practice/pdfs/ g10090.pdf (Accessed April 2004) Comprehensive and systematic meta-analysis of randomized clinical trials of drugs used in migraine prevention, including a very extensive reference list.
   Google Scholar
• Topirarnate approvable letter November 18, 2003 www.docguide.cominews/content.nsfinews/8525697700573E1885256DE2006DD908? OpenDocument&c = Migraine &count = 10 (Accessed April 2004)
   Google Scholar